News | March 18, 2026
Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
Dilip Shanghvi to continue as the Executive Chairman of the Board
The company will also share results in two additional posters for deuruxolitinib
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Subscribe To Our Newsletter & Stay Updated
